Open Access<p>Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling</p>
Author(s) -
Xiaoxiao Cai,
Bin Wei,
Lele Li,
Xiaofeng Chen,
Jing Yang,
Xiaofei Li,
Xiaozheng Jiang,
Mu Lv,
Mingyang Li,
Yumeng Lin,
Qiang Xu,
Wenjie Guo,
Yanhong Gu
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s266549
Subject(s) - apatinib , cancer research , angiogenesis , medicine , kinase insert domain receptor , catenin , protein kinase b , colorectal cancer , vascular endothelial growth factor , cancer , signal transduction , chemistry , vascular endothelial growth factor a , wnt signaling pathway , vegf receptors , biochemistry
Apatinib is an inhibitor of VEGFR2 (vascular endothelial growth factor receptor 2) that has attracted a great deal of attention due to its promotion of anticancer activity. In the present study, we investigated the therapeutic effects of apatinib against colorectal cancer (CRC) and examined the underlying mechanism.